TBC1D19 Inhibitors
TBC1D19 inhibitors are a class of chemical compounds designed to selectively interfere with the function of the TBC1D19 protein, which is implicated in cellular trafficking processes, particularly those involving endosome-to-Golgi transport. The inhibition of TBC1D19 can have profound effects on the cellular trafficking machinery, as TBC1D19 is known to act as a GTPase-activating protein (GAP) for Rab family proteins, which are essential regulators of intracellular vesicle transport. The specific inhibition of TBC1D19 by these compounds disrupts its GAP activity, leading to an alteration in the dynamic balance of GTP-bound and GDP-bound forms of Rab proteins. This disruption can consequently impair vesicle formation, movement, and the fusion process that is vital for the proper flow of proteins and lipids within the cell. The inhibition mechanism primarily revolves around the binding of these inhibitors to the TBC1D19 protein, obstructing its interaction with Rab proteins and thus its capacity to catalyze the hydrolysis of GTP to GDP on these small GTPases, leading to a dysregulation of the endosomal trafficking pathways.
The chemical inhibitors targeting TBC1D19 are characterized by their molecular specificity, which allows them to bind selectively to the TBC domain of the protein. This specificity is crucial to ensure that the inhibitors do not inadvertently affect other proteins with similar domains or activities within the cell. By focusing on the TBC domain, these inhibitors capitalize on a unique feature of TBC1D19, as this domain is responsible for its GAP activity towards Rab proteins. The action of these inhibitors leads to a buildup of GTP-bound Rabs, which can result in the misdirection or aggregation of vesicles within the cell, ultimately hampering cellular homeostasis. The biochemical pathways affected by the disruption of TBC1D19 function include those related to membrane trafficking, organelle organization, and the maintenance of the cytoskeletal network, which are essential for the proper functioning of various cellular processes. As such, TBC1D19 inhibitors play a pivotal role in deciphering the complex regulatory mechanisms of cellular transport and offer a valuable tool for studying the underlying principles of vesicle trafficking and its impact on cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3K, wortmannin disrupts the PI3K/AKT pathway, which can indirectly lead to reduced activity of TBC1D19 due to TBC1D19's role in endosome dynamics, which are influenced by signals from the PI3K/AKT pathway. | ||||||
YM201636 | 371942-69-7 | sc-204193 | 5 mg | $217.00 | 6 | |
YM201636 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KB). By inhibiting PI4KB, YM201636 impairs the production of phosphatidylinositol 4-phosphate, a lipid that recruits TBC1D19 to specific cellular compartments. This results in the functional inhibition of TBC1D19's role in membrane trafficking. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42, a member of the Rho family of GTPases. Cdc42 is involved in actin filament assembly. Inhibition of Cdc42 can alter actin dynamics, which in turn may affect the trafficking of endosomes where TBC1D19 exerts its function. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 is an inhibitor of cytohesins, which are guanine nucleotide exchange factors (GEFs) for ARF GTPases. By inhibiting cytohesins, SecinH3 can indirectly affect ARF GTPase activity and thus the endosomal function where TBC1D19 is involved. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin B disrupts microfilament organization by binding to actin monomers, thereby preventing their polymerization. As actin dynamics are essential for membrane trafficking, the inhibition of actin polymerization can indirectly affect the function of TBC1D19 in endosomal trafficking. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF) GTPase activating proteins (GAPs) and blocks the activation of ARF1. By disrupting ARF1 function, it indirectly hampers the vesicle trafficking pathways that are crucial for TBC1D19’s role in endosomal dynamics. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 is an inhibitor of the Rac1 GTPase, which is involved in cytoskeletal reorganization. By inhibiting Rac1, NSC23766 can alter cytoskeletal dynamics, which may in turn affect endocytic and exocytic pathways where TBC1D19 is functionally significant. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a non-competitive inhibitor of the GTPase activity of dynamin. It impedes endocytosis, which is a process that TBC1D19 is associated with, especially in the regulation of endosomal sorting and trafficking. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is an inhibitor of the exocyst complex, which is involved in tethering vesicles to the plasma membrane. By inhibiting this complex, Exo1 can indirectly interfere with vesicle transport and membrane trafficking processes where TBC1D19 is implicated. | ||||||